Midi Health Review: GLP-1 Provider & Genetic Testing

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Midi Health is a telehealth company that launched in 2022, focusing on GLP-1 prescription and ongoing weight management support. The platform claims to serve over 150,000 patients and partners with licensed healthcare providers to deliver remote care. Unlike traditional weight-loss clinics, Midi Health integrates telemedicine with medication management, appealing to patients seeking convenience and privacy.

For anyone exploring GLP-1 providers and compounded peptide options, understanding how platforms like Midi Health operate—and how they differ from precision-genetics-informed alternatives—matters. PlexusDx emphasizes compounded semaglutide and tirzepatide from licensed 503A pharmacies, paired with optional biomarker insight via Precision Peptide Genetic Testing, to help patients and providers make more informed decisions.

What Midi Health Offers: Platform Overview and Service Model

Midi Health operates as a direct-to-consumer telehealth service, connecting patients with board-certified healthcare providers via video consultation. The platform prescribes both branded GLP-1 medications (such as Ozempic, Wegovy, and Mounjaro) and compounded versions, depending on availability and patient preference. Patients complete an initial health assessment, including lab work in some cases, before a provider consultation.

Midi Health's pricing typically includes monthly membership ($99–$299) plus medication costs, which vary based on whether patients choose branded or compounded formulations. The company emphasizes rapid onboarding—many users report consultations within days. However, the platform does not systematically offer genetic pathway testing as part of its standard intake, focusing instead on clinical history and metabolic markers.

Provider Assessment and Screening: Midi Health vs. Genetic-Informed Alternatives

Midi Health providers conduct standard medical screening during virtual consultations, reviewing cardiovascular history, diabetes risk, thyroid function, and current medications. This approach aligns with FDA guidance for GLP-1 safety. However, the platform does not routinely integrate peptide-pathway genetic testing into its decision framework, instead relying on clinical indicators and patient-reported outcomes to guide medication selection.

Assessment Factor	Midi Health Approach	Precision-Genetics-Informed Model
Initial Screening	Clinical history, labs, cardiovascular review	Clinical history + optional peptide genetic pathway testing
Genetic Biomarker Testing	Not routinely offered as standard	Precision Peptide Genetic Test available ($99–$298)
Medication Selection Logic	Provider judgment + patient preference	Clinical assessment informed by GLP1R, GIPR, FTO variants
Ongoing Monitoring	Telemedicine follow-up, symptom tracking	Biomarker context + provider communication support

Medication Options: Branded vs. Compounded Availability

Midi Health offers both branded GLP-1 medications and compounded alternatives. Branded options (Ozempic, Wegovy, Mounjaro) are available subject to supply and insurance coverage, while compounded semaglutide and tirzepatide may offer faster access and lower out-of-pocket cost for uninsured or underinsured patients. Midi Health does not manufacture its own medications but works with licensed pharmacies to fulfill prescriptions.

Compounded GLP-1 peptides from licensed 503A pharmacies carry the same regulatory oversight as branded injectables but are not FDA-approved as finished products. Patients should understand that compounded medications, while clinically used off-label, require a valid prescription and ongoing provider supervision. Midi Health's availability of compounded options varies by state and insurance status.

Cost, Insurance, and Access: Midi Health Pricing Structure

Midi Health membership ranges from $99 to $299 monthly, covering telehealth access and provider consultations. Medication costs depend on formulation: branded GLP-1 drugs typically cost $900–$1,500 monthly out-of-pocket (though insurance may cover some), while compounded semaglutide and tirzepatide via Midi Health generally range from $200–$400 monthly. Patients without insurance may find compounded options more affordable than branded alternatives.

Insurance coverage for Midi Health depends on whether the prescribed medication is covered under a patient's plan. Branded medications like Wegovy are increasingly covered if medically necessary, though prior authorization is common. Compounded peptides are rarely covered by insurance, making Midi Health's pricing relevant primarily for cash-pay patients. PlexusDx compounded semaglutide starts at $179/month and tirzepatide at $229/month, comparable to Midi Health's compounded-medication pricing.

Clinical Efficacy and Real-World Outcomes: What the Evidence Shows

GLP-1 receptor agonists consistently achieve 10–22% weight loss in clinical trials, with higher outcomes in patients with obesity and metabolic dysfunction. Midi Health patients report similar weight-loss trajectories in user testimonials and published case data, though rigorous outcome tracking varies across the platform. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most commonly prescribed GLP-1 agents, both supported by large randomized controlled trials.

Individual response to GLP-1 therapy depends on dose tolerance, adherence, lifestyle factors, and underlying metabolic health. Some patients experience robust appetite suppression and metabolic improvement within weeks; others require dose escalation or adjustment of formulation. Genetic variation in GLP1R, GIPR, and FTO may influence response magnitude and side-effect tolerance, although this understanding is still emerging and should not replace clinical judgment.

Safety, Side Effects, and Medical Contraindications

GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and uncontrolled diabetic retinopathy. Common side effects include nausea, vomiting, constipation, and appetite loss, typically mild and transient. Serious adverse events (pancreatitis, gallstone formation, acute kidney injury) are rare but require immediate medical attention. Midi Health providers screen for these contraindications during consultation.

Patients starting GLP-1 therapy should be monitored for dehydration, electrolyte imbalance, and gastroparesis symptoms, especially at higher doses. Both Midi Health and precision-informed providers emphasize lifestyle support—adequate hydration, balanced nutrition, and gradual dose titration—to minimize adverse effects. Pregnant or nursing patients should not use GLP-1 agents and should consult their provider before conception.

How PlexusDx Supports a More Personalized Approach

Genetic variation in peptide-pathway genes (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) may help provide context for individual GLP-1 response and metabolic phenotype, though these findings should not be interpreted as deterministic. PlexusDx Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in these pathways to support more informed conversations between patients and providers about which GLP-1 formulation—semaglutide, tirzepatide, or emerging peptides—may align with a patient's genetic background.

Unlike Midi Health's standard clinical-only screening, PlexusDx integrates genetic pathway insight into the provider consultation. This does not guarantee superior outcomes, but it may reduce trial-and-error medication adjustments and help providers personalize dosing strategies. The Precision Peptide Genetic Test predicts predispositions, not exact medication response; results should always be interpreted by a qualified healthcare provider in conjunction with clinical assessment and patient preference.

If you are considering GLP-1 therapy through Midi Health or another telehealth platform, discussing genetic and biomarker data with your provider can deepen the clinical conversation. PlexusDx's optional genetic test and compounded GLP-1 options (compounded semaglutide from $179/month or compounded tirzepatide from $229/month) from licensed 503A pharmacies offer an alternative pathway for patients seeking both biomarker context and medication access.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is Midi Health, and how does it differ from traditional weight-loss clinics?

Midi Health is a telehealth platform founded in 2022 that connects patients with remote providers for GLP-1 prescription and weight management. Unlike in-person clinics, Midi Health operates entirely online, offers rapid consultations, and provides both branded and compounded medication options, prioritizing speed and convenience over intensive ...

Does Midi Health offer genetic testing to inform GLP-1 selection?

Midi Health does not routinely offer genetic pathway testing as part of standard intake. The platform relies on clinical history, lab markers, and provider judgment to guide medication choice. Patients interested in genetic biomarker context should discuss this separately with their Midi Health provider or explore alternative platforms offering ...

How much does Midi Health cost compared to other GLP-1 providers?

Midi Health membership is $99–$299 monthly, plus medication costs ($200–$400 for compounded, $900–$1,500 for branded, out-of-pocket). PlexusDx compounded semaglutide starts at $179/month and tirzepatide at $229/month, offering comparable or lower medication pricing without a separate membership fee.

Is Midi Health's compounded GLP-1 medication safe and legal?

Yes, compounded GLP-1 medications from licensed 503A pharmacies are legal and safe when prescribed by a qualified provider. They are not FDA-approved as finished products but are clinically used off-label. Midi Health partners with accredited compounding pharmacies, ensuring quality and compliance.

What should I do if I want genetic insight into my GLP-1 response?

PlexusDx Precision Peptide Genetic Test can reveal predispositions in GLP1R, GIPR, FTO, and MC4R pathways to support provider conversations. This test may help personalize your GLP-1 choice and dosing strategy, though results should always be interpreted by your healthcare provider alongside clinical assessment.

Midi Health Review: GLP-1 Selection and Genetic Biomarker Context

Midi Health is a telehealth platform offering GLP-1 medications and weight management support. This review examines how Midi Health structures its provider assessment, genetic screening options, and medication access compared to precision-focused alternatives like PlexusDx.